Peppermint Oil

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion pain focus

Research Overview

Research on peppermint oil has been most extensively developed in gastrointestinal (GI) disorders—particularly irritable bowel syndrome (IBS)—with additional, smaller bodies of work on functional dyspepsia and other GI-related indications (e.g., nausea, procedural facilitation in endoscopy). Mechanistic and physiological studies summarized in narrative reviews describe plausible GI-relevant actions, including smooth muscle relaxation (e.g., calcium-channel–mediated antispasmodic effects), modulation of visceral sensitivity via transient receptor potential channels, and potential antimicrobial and anti-inflammatory activities. Outside GI medicine, peppermint oil has also been investigated for antimicrobial activity against oral/endodontic pathogens in vitro, and formulation research has explored nanoemulsions to improve solubility/stability and enhance antibacterial effects in laboratory models.

The strongest clinical evidence supports peppermint oil as a short-term symptomatic therapy for IBS. A dedicated meta-analysis of randomized controlled trials (RCTs) reported improvements in global IBS symptoms and abdominal pain versus placebo, and a larger network meta-analysis comparing “traditional” IBS therapies ranked peppermint oil highly for global symptom response over 4–12 weeks, though it noted that relatively few included trials were at low risk of bias and that head-to-head differences between active treatments were not clearly demonstrated. Across these syntheses, peppermint oil appears generally well tolerated in trial settings, with comparatively few adverse effects reported, although safety conclusions are constrained by trial duration and reporting quality.

Key research gaps include higher-quality, adequately powered RCTs with rigorous methodology, standardized peppermint oil formulations (e.g., dose, enteric coating, release characteristics), and longer follow-up to establish durability of benefit and longer-term safety in IBS and other functional GI disorders. More direct head-to-head trials versus other first-line IBS options (e.g., soluble fiber, antispasmodics, neuromodulators) are needed to clarify comparative effectiveness and patient subgroup effects (e.g., IBS subtype). For non-GI applications, much of the evidence remains preclinical (e.g., antimicrobial assays, nanoemulsion studies), and translation to clinically meaningful outcomes will require well-designed human studies that link formulation advances and in vitro activity to real-world efficacy and safety.

1. What conditions has Peppermint Oil been studied for?

  • Irritable bowel syndrome (IBS) (multiple randomized controlled trials and meta-analyses; outcomes include global IBS symptoms and abdominal pain over ~4–12 weeks).

  • Functional dyspepsia (reviewed as an indication with randomized trials; also mentioned as a functional GI disorder where nonpharmacologic options are explored).

  • Childhood functional abdominal pain (placebo-controlled studies mentioned in the 2017 review).

  • Post-operative nausea (placebo-controlled studies mentioned in the 2017 review).

  • Procedural GI uses: facilitating completion of colonoscopy and endoscopic retrograde cholangiopancreatography (ERCP) (mentioned in the 2017 review).

  • Antimicrobial applications (preclinical/in vitro):

    • Against endodontic pathogens (MIC/MBC/MFC testing in vitro).

    • Against bacteria such as E. coli and S. aureus (peppermint oil nanoemulsion study; includes cell-line toxicity testing).

2. Does it work in treating those conditions? Summarize the evidence.

  • IBS: Yes, evidence supports benefit vs placebo, but certainty is limited.

    • A 2019 network meta-analysis of “traditional therapies” for IBS (51 RCTs, 4644 patients; only 13 low risk of bias) ranked peppermint oil capsules first for improving global IBS symptoms at 4–12 weeks (RR for failure to improve 0.63; 95% CI 0.48–0.83). Authors emphasized considerable uncertainty due to trial quality and limited long-term data.

    • A 2016/2017 systematic review and meta-analysis (12 RCTs, 835 patients) found peppermint oil improved global IBS symptoms vs placebo (RR 2.39; 95% CI 1.93–2.97, based on 7 RCTs contributing to that outcome) and concluded it was safe and effective for pain and global symptoms.

    • An updated meta-analysis to April 2022 (10 RCTs, 1030 patients) found peppermint oil superior to placebo for:

      • Global IBS symptoms: RR of not improving 0.65 (95% CI 0.43–0.98); NNT ≈ 4 (with a very wide CI for NNT, reflecting imprecision).

      • Abdominal pain: RR of pain not improving 0.76 (95% CI 0.62–0.93); NNT ≈ 7.

    • However, the 2022 analysis rated the quality of evidence as very low and called for adequately powered RCTs, especially as first-line therapy.

  • Functional dyspepsia: Possibly beneficial, but the abstracts here do not provide effect sizes.

    • The 2017 peppermint oil review states placebo-controlled studies support use in functional dyspepsia, but the provided abstract does not quantify benefit.

    • A separate functional dyspepsia overview notes that available therapies overall are not effective for most patients and that results across treatments can be conflicting; it does not provide peppermint-oil-specific efficacy estimates in the excerpt provided.

  • Childhood functional abdominal pain and post-operative nausea: Some supportive placebo-controlled studies are mentioned, but details are not provided in these abstracts.

  • Antimicrobial effects: Demonstrated in vitro; clinical effectiveness for infections is not established by these abstracts.

    • In vitro testing showed peppermint oil had antimicrobial activity against common endodontic pathogens (MIC/MBC/MFC methods described).

    • A peppermint oil nanoemulsion inhibited E. coli in lab experiments; this is not evidence of clinical infection treatment.

3. What health benefits does it have?

  • IBS symptom relief (best-supported benefit in these abstracts):

    • Improvement in global IBS symptoms and abdominal pain vs placebo in meta-analyses (including 2016/2017 and 2022).

  • Antispasmodic/smooth muscle relaxation effects relevant to GI cramping:

    • The 2017 review describes mechanisms including smooth muscle relaxation (via calcium channel blockade or enteric nervous system effects) and visceral sensitivity modulation (via transient receptor potential channels).

  • Potential GI-physiology effects across the GI tract:

    • The 2017 review notes effects on oesophageal, gastric, small bowel, gallbladder, and colonic physiology, and use in facilitating colonoscopy/ERCP completion (procedural benefit rather than a chronic “health benefit”).

  • Antimicrobial and anti-inflammatory properties (mostly mechanistic/preclinical):

    • The 2017 review lists antimicrobial and anti-inflammatory activity as possible mechanisms.

    • In vitro studies show antimicrobial activity against oral/endodontic pathogens and bacteria such as E. coli.

4. Does it have any downsides or side effects?

  • Adverse events may be more frequent than placebo in IBS trials.

    • The 2022 meta-analysis found higher risk of “any adverse event” with peppermint oil vs placebo (RR 1.57; 95% CI 1.04–2.37).

  • Overall tolerability is often described as good, but reporting may be limited.

    • The 2017 review states few adverse effects were reported in peppermint oil trials, but this may reflect trial size, duration, and reporting practices.

  • Evidence limitations that affect risk/benefit interpretation:

    • The 2019 network meta-analysis noted that only a minority of RCTs were low risk of bias and that most trials were short (4–12 weeks), leaving long-term safety and efficacy uncertain.

    • The 2022 meta-analysis rated the overall evidence as very low quality.

  • Non-clinical safety note (lab study):

    • In a nanoemulsion study, a bronchial epithelial cell line (BEAS-2B) had <10% apoptosis vs control at tested concentrations (0.02–0.2 μg/μL). This is not directly translatable to oral supplement safety but suggests low cytotoxicity under those experimental conditions.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic (gene–response) findings are provided in these abstracts for peppermint oil. The included evidence focuses on clinical outcomes in IBS and mechanistic hypotheses (e.g., calcium channel blockade, transient receptor potential channels), but does not link efficacy or adverse effects to specific genetic variants. Therefore, based on these abstracts, there is insufficient evidence to say peppermint oil is beneficial or harmful for any particular genetic variation.

References

  1. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.
    Christopher J Black, Yuhong Yuan, Christian P Selinger, Michael Camilleri, Eamonn M M Quigley, Paul Moayyedi, Alexander C Ford (2020) - The lancet. Gastroenterology & hepatology
  2. Estimation of MBC: MIC Ratio of Herbal Extracts against Common Endodontic Pathogens.
    Chetana S Makade, Pratima R Shenoi, Bhoomendra A Bhongade, Shrikant A Shingane, Prajakta C Ambulkar, Akhilesh M Shewale (2024) - Journal of pharmacy & bioallied sciences
  3. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.
    B P Chumpitazi, G L Kearns, R J Shulman (2018) - Alimentary pharmacology & therapeutics
  4. Review article: treatment options for functional dyspepsia.
    Imke Masuy, Lukas Van Oudenhove, Jan Tack (2019) - Alimentary pharmacology & therapeutics
  5. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data.
    N Alammar, L Wang, B Saberi, J Nanavati, G Holtmann, R T Shinohara, G E Mullin (2019) - BMC complementary and alternative medicine
  6. Preparation of peppermint oil nanoemulsions: Investigation of stability, antibacterial mechanism and apoptosis effects.
    Qi Liu, Yuan Gao, Xuan Fu, Wang Chen, Jinghan Yang, Zhiyang Chen, Zixuan Wang, Xiangxun Zhuansun, Jianguo Feng, Yong Chen (2021) - Colloids and surfaces. B, Biointerfaces
  7. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
    Diego Currò, Gianluca Ianiro, Silvia Pecere, Stefano Bibbò, Giovanni Cammarota (2017) - British journal of pharmacology
  8. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
    Maria Rosa Ingrosso, Gianluca Ianiro, Judy Nee, Anthony J Lembo, Paul Moayyedi, Christopher J Black, Alexander C Ford (2022) - Alimentary pharmacology & therapeutics
  9. Essential oils, their therapeutic properties, and implication in dentistry: A review.
    Namrata Dagli, Rushabh Dagli, Rasha Said Mahmoud, Kusai Baroudi (2015) - Journal of International Society of Preventive & Community Dentistry
  10. Co-encapsulation of borage seed oil and peppermint oil blends within ultrasound-assisted soy protein isolate/purity gum ultra complex nanoparticles: Fabrication, structural interaction mechanisms, and in vitro digestion studies.
    Abdur Rehman, Ibrahim Khalifa, Hafiz Abdul Rasheed, Muhammad Waheed Iqbal, Muhammad Shoaib, Junxia Wang, Yongjun Zhao, Qiufang Liang, Mingming Zhong, Yufan Sun, Tawfiq Alsulami, Xiaofeng Ren, Song Miao (2025) - Food chemistry
  11. Effects of aromatherapy on nausea and vomiting in patients with cancer: A systematic review and meta-analysis of randomized controlled trials.
    Ju Hyun Ahn, Myoungsuk Kim, Ri Whaol Kim (2024) - Complementary therapies in clinical practice
  12. Best management of irritable bowel syndrome.
    Christopher J Black, Alexander Charles Ford (2021) - Frontline gastroenterology
  13. The Effects of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy: An Open Label Quasi-Randomized Controlled Pilot Study.
    Nuriye Efe Ertürk, Sultan Taşcı (2021) - Complementary therapies in medicine
  14. Pharmacologic treatment in pediatric functional abdominal pain disorders: a systematic review.
    Judith J Korterink, Juliette M T M Rutten, Leonie Venmans, Marc A Benninga, Merit M Tabbers (2015) - The Journal of pediatrics
  15. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial.
    Judy Nee, Sarah Ballou, John M Kelley, Ted J Kaptchuk, William Hirsch, Jesse Katon, Vivian Cheng, Vikram Rangan, Anthony Lembo, Johanna Iturrino (2021) - The American journal of gastroenterology
  16. Herbs and Spices in the Treatment of Functional Gastrointestinal Disorders: A Review of Clinical Trials.
    Amanda C Fifi, Cara Hannah Axelrod, Partha Chakraborty, Miguel Saps (2018) - Nutrients
  17. Review article: current and future treatment approaches for pain in IBS.
    Peter Paine (2021) - Alimentary pharmacology & therapeutics
  18. Art of Prevention: Essential Oils - Natural Products Not Necessarily Safe.
    Allison Sindle, Kari Martin (2021) - International journal of women's dermatology
  19. In vitro antiviral activities of thymol and Limonin against influenza a viruses and SARS-CoV-2.
    Gomaa Mostafa-Hedeab, Akram Hegazy, Islam Mostafa, Ibrahim H Eissa, Ahmed M Metwaly, Hany Abdelfattah Elhady, Abozer Y Eledrdery, Sager Holyl Alruwaili, Alaa Oqalaa E Alibrahim, Fawaz O Alenazy, Muhannad Faleh Alanazi Alruwaili, Thamer Alshami Marghel, Muharib Alruwaili, Alaaeldin Mohamed Saad, Mahmoud Bayoumi, Assem Mohamed El-Shazly, Luis Martinez-Sobrido, Ahmed Mostafa (2025) - Scientific reports
  20. Improved antioxidant activity and delivery of peppermint oil Pickering emulsion stabilized by resveratrol-grafted zein covalent conjugate/quaternary ammonium chitosan nanoparticles.
    Gerui Ren, Jiacheng Liu, Jieyu Shi, Ying He, Ying Zhu, Yujing Zhan, Junfei Lv, Lei Liu, Ying Huang, Min Huang, Wenjun Fang, Qunfang Lei, Hujun Xie (2023) - International journal of biological macromolecules


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!